- Home
- EPSN vs DMAC Comparison
EPSN vs DMAC Comparison
Compare EPSN & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPSN
- DMAC
- Stock Information
- Founded
- EPSN 2005
- DMAC 2000
- Country
- EPSN Canada
- DMAC United States
- Employees
- EPSN N/A
- DMAC N/A
- Industry
- EPSN Oil & Gas Production
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- EPSN Energy
- DMAC Health Care
- Exchange
- EPSN Nasdaq
- DMAC Nasdaq
- Market Cap
- EPSN 155.9M
- DMAC 178.0M
- IPO Year
- EPSN N/A
- DMAC N/A
- Fundamental
- Price
- EPSN $7.27
- DMAC $4.12
- Analyst Decision
- EPSN Strong Buy
- DMAC Strong Buy
- Analyst Count
- EPSN 1
- DMAC 2
- Target Price
- EPSN $7.00
- DMAC $8.00
- AVG Volume (30 Days)
- EPSN 82.0K
- DMAC 99.4K
- Earning Date
- EPSN 05-14-2025
- DMAC 05-13-2025
- Dividend Yield
- EPSN 3.42%
- DMAC N/A
- EPS Growth
- EPSN N/A
- DMAC N/A
- EPS
- EPSN 0.20
- DMAC N/A
- Revenue
- EPSN $39,699,172.00
- DMAC N/A
- Revenue This Year
- EPSN $41.35
- DMAC N/A
- Revenue Next Year
- EPSN N/A
- DMAC N/A
- P/E Ratio
- EPSN $35.87
- DMAC N/A
- Revenue Growth
- EPSN 35.21
- DMAC N/A
- 52 Week Low
- EPSN $4.95
- DMAC $2.14
- 52 Week High
- EPSN $7.54
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- EPSN 58.74
- DMAC 51.05
- Support Level
- EPSN $6.91
- DMAC $4.00
- Resistance Level
- EPSN $7.35
- DMAC $4.33
- Average True Range (ATR)
- EPSN 0.26
- DMAC 0.28
- MACD
- EPSN 0.02
- DMAC 0.02
- Stochastic Oscillator
- EPSN 64.84
- DMAC 46.87
About EPSN Epsilon Energy Ltd. Common Share
Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.